文献速递淋巴瘤

PLK1抑制通过激活纺锤体组装检查点增强Brentuximab vedotin对CD30阳性T细胞淋巴瘤的疗效

PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation.
PubMed 文献 · Leukemia · 2026-07-13

本研究在外周T细胞淋巴瘤(PTCL)中探索增强Brentuximab vedotin(BV)疗效的策略。通过全基因组CRISPR-Cas9筛选发现纺锤体组装检查点(SAC)缺陷是BV敏感因素,继而细胞周期化学筛选鉴定PLK1抑制剂(volasertib)与BV协同。联合治疗在CD30阳性PTCL细胞系及PDX模型中显示协同细胞毒性与肿瘤生长抑制,并延长生存。

要点

  • PLK1抑制剂volasertib在多个CD30阳性PTCL细胞系中增强BV诱导的细胞毒性。
  • BV-volasertib联合通过激活SAC诱导持续有丝分裂阻滞、有丝分裂灾难、凋亡和DNA损伤。
  • 联合治疗在细胞系衍生和患者衍生异种移植模型中显著抑制肿瘤生长并延长生存。

核心结论

  • PLK1抑制通过激活SAC增强BV对CD30阳性PTCL的疗效,联合治疗具有克服治疗抵抗的潜力。

研究设计与样本

  • 研究基于全基因组CRISPR-Cas9筛选和细胞周期聚焦化学筛选,在CD30阳性PTCL细胞系及细胞系衍生和患者衍生异种移植模型中进行验证。

主要发现

  • volasertib在多个CD30阳性PTCL细胞系中持续增强BV诱导的细胞毒性。
  • BV-volasertib联合诱导持续有丝分裂阻滞,随后出现有丝分裂灾难、凋亡和DNA损伤。
  • 选择性Mps1抑制剂进一步支持该联合对SAC的依赖性。
  • 联合治疗在细胞系衍生和患者衍生异种移植模型中显著抑制肿瘤生长并延长生存。

关键数值与推荐

  • 全基因组CRISPR-Cas9筛选识别SAC调控缺陷为BV敏感因素。
  • 细胞周期聚焦化学筛选鉴定PLK1抑制剂为BV的协同伙伴。

临床怎么用

  • 在CD30阳性PTCL中,BV联合PLK1抑制剂(如volasertib)可能增强疗效并克服耐药。
  • SAC激活状态可能作为BV联合PLK1抑制策略的生物标志物方向。

局限性

  • 研究主要基于细胞系和异种移植模型,尚未报告临床人体试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies with poor clinical outcomes and limited treatment options. Brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate, has shown efficacy in CD30-positive PTCLs but is frequently associated with incomplete responses and relapse. To enhance its therapeutic effect, we previously identified defects in spindle assembly checkpoint (SAC) regulation as key sensitizers to BV via a genome-wide CRISPR-Cas9 screen. Building on this, we conducted a cell cycle-focused chemical screen and identified polo-like kinase 1 (PLK1) inhibitors as potent synergistic partners for BV. Among them, volasertib consistently enhanced BV-induced cytotoxicity across multiple CD30-positive PTCL cell lines. Mechanistically, the BV-volasertib combination induced sustained mitotic arrest through activation of the SAC, followed by mitotic catastrophe, apoptosis, and DNA damage. This SAC dependence was further supported by the use of a selective Mps1 inhibitor. Importantly, the combination significantly suppressed tumor growth and prolonged survival in both cell line-derived and patient-derived xenograft (PDX) models. These findings underscore the therapeutic potential of combining BV with PLK1 inhibition, and highlight SAC activation as a key mechanism to overcome therapeutic resistance in CD30-positive PTCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mori Y, Suto K, Takei N, et al. PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation. Leukemia. 2026. PMID: 42443409. doi:10.1038/s41375-026-03055-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。